Vaccines: 53-84% vs Delta infection, 85-96% vs hospitalization
covid1.substack.com
Do Delta ‘breakthroughs’ really mean vaccine protection is waning, and are boosters the answer? [Science News report.] “[Vaccine] efficacy drops with Delta. That is indisputable,” says Leif Erik Sander, an infectious disease expert at the Charité University Hospital in Berlin. But exactly how much it drops differs across studies. In a report this week analyzing weekly reports on nursing home residents across the United States, researchers found that the messenger RNA (mRNA) vaccines made by Pfizer and Moderna had an efficacy against all infections that went from 75% pre-Delta to 53% after it took over. (The variant accounts for more than 90% of U.S. cases now.). “Protection against hospitalization looks quite stable,” Sander says. In the New York study, for example, vaccine efficacy against hospitalization for COVID-19 stayed close to 95%. Data from the Israeli Ministry of Health suggests protection against severe disease is still nearly 92% for people 50 and younger and 85% for those older than 50. Public Health England estimates that two doses of vaccine provide 96% protection against hospitalization.
Vaccines: 53-84% vs Delta infection, 85-96% vs hospitalization
Vaccines: 53-84% vs Delta infection, 85-96…
Vaccines: 53-84% vs Delta infection, 85-96% vs hospitalization
Do Delta ‘breakthroughs’ really mean vaccine protection is waning, and are boosters the answer? [Science News report.] “[Vaccine] efficacy drops with Delta. That is indisputable,” says Leif Erik Sander, an infectious disease expert at the Charité University Hospital in Berlin. But exactly how much it drops differs across studies. In a report this week analyzing weekly reports on nursing home residents across the United States, researchers found that the messenger RNA (mRNA) vaccines made by Pfizer and Moderna had an efficacy against all infections that went from 75% pre-Delta to 53% after it took over. (The variant accounts for more than 90% of U.S. cases now.). “Protection against hospitalization looks quite stable,” Sander says. In the New York study, for example, vaccine efficacy against hospitalization for COVID-19 stayed close to 95%. Data from the Israeli Ministry of Health suggests protection against severe disease is still nearly 92% for people 50 and younger and 85% for those older than 50. Public Health England estimates that two doses of vaccine provide 96% protection against hospitalization.